文献速递乳腺癌

BIG 1-98研究:绝经后ER阳性/HER2阴性早期乳腺癌晚期远处复发的驱动基因改变

Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.
PubMed 文献 · Ann Oncol · 2020-07-08

该研究对BIG 1-98试验中764例绝经后ER阳性/HER2阴性早期乳腺癌患者进行二代测序,成功测序538例(70%),中位随访8.1年,识别与晚期远处复发相关的驱动基因改变。单变量分析显示PIK3CA突变与晚期远处复发风险降低相关,8p11扩增和BRCA2突变与风险增加相关;多变量分析中仅8p11扩增和BRCA2突变保持显著。

要点

  • PIK3CA突变(58.8%)与晚期远处复发风险降低显著相关(HR 0.40,95%CI 0.20-0.82,P=0.012)。
  • 8p11扩增(10.9%)与晚期远处复发风险增加显著相关(HR 4.79,95%CI 2.30-9.97,P<0.001)。
  • BRCA2突变(2.3%)与晚期远处复发风险增加显著相关(HR 5.39,95%CI 1.51-19.29,P=0.010)。

核心结论

  • 在绝经后ER阳性/HER2阴性早期乳腺癌中,PIK3CA突变与晚期远处复发风险降低相关,8p11扩增和BRCA2突变与风险增加相关。

研究设计与样本

  • 基于BIG 1-98随机试验,对764例绝经后ER阳性/HER2阴性早期乳腺癌患者的原发肿瘤进行二代测序。
  • 晚期远处复发定义为随机化后≥5年,采用Cox回归模型评估驱动改变与远处无复发生存期的关联,并进行多变量分析和加权分析。

主要发现

  • 538/764例(70%)样本成功测序,中位随访8.1年,包括88例(63%)早期和52例(37%)晚期远处复发事件。
  • 单变量分析中,PIK3CA突变(58.8%)与晚期远处复发风险降低显著相关(HR 0.40,95%CI 0.20-0.82,P=0.012)。
  • 单变量分析中,8p11扩增(10.9%)与晚期远处复发风险增加显著相关(HR 4.79,95%CI 2.30-9.97,P<0.001)。
  • 单变量分析中,BRCA2突变(2.3%)与晚期远处复发风险增加显著相关(HR 5.39,95%CI 1.51-19.29,P=0.010)。
  • 多变量分析中,仅8p11扩增(P=0.002)和BRCA2突变(P=0.013)仍为显著预测因素。

临床怎么用

  • 驱动基因改变的特征分析可能有助于优化晚期疾病治疗选择,并识别未来试验的潜在药物靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, the risk for distant recurrence can extend beyond 5 years of adjuvant endocrine therapy. This study aims to identify genomic driver alterations associated with late distant recurrence. PATIENTS AND METHODS: Next generation sequencing was used to characterize driver alterations in primary tumors from a subset of 764 postmenopausal estrogen receptor-positive/HER2-negative patients from the BIG 1-98 randomized trial. Late distant recurrence events were defined as ≥5 years from time of randomization). The association of driver alterations with distant recurrence-free interval in early and late time periods was assessed using Cox regression models. Multivariable analyses were carried out to adjust for clinicopathological factors. Weighted analysis methods were used in order to correct for over-sampling of distant recurrences. RESULTS: A total of 538 of 764 (70%) samples were successfully sequenced including 88 (63%) early and 52 (37%) late distant recurrence events after a median follow up of 8.1 years. In univariable analysis for late distant recurrence, PIK3CA mutations (58.8%) were significantly associated with reduced risk [hazard ratio (HR) 0.40, 95% confidence interval (CI) 0.20-0.82, P = 0.012], whereas amplifications on chromosome 8p11 (10.9%) (HR 4.79, 95% CI 2.30-9.97, P < 0.001) and BRCA2 mutations (2.3%) (HR 5.39, 95% CI 1.51-19.29, P = 0.010) were significantly associated with an increased risk. In multivariable analysis, only amplifications on 8p11 (P = 0.002) and BRCA2 mutations (P = 0.013) remained significant predictors. CONCLUSIONS: In estrogen receptor-positive/HER2-negative postmenopausal early breast cancer, PIK3CA mutations were associated with reduced risk of late distant recurrence, whereas amplifications on 8p11 and BRCA2 mutations were associated with increased risk of late distant recurrence. The characterization of oncogenic driver alterations may aid in refining treatment choices in the late disease setting, and help identify potential drug targets for testing in future trials.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Luen SJ, Asher R, Lee CK, et al. Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. Ann Oncol. 2020. PMID: 32652112. doi:10.1016/j.annonc.2020.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。